808 related articles for article (PubMed ID: 26537358)
41. Management and Clinical Outcomes of Membranous Nephropathy, IgA Nephropathy, and Minimal Change Disease Two Years Post-Kidney Biopsy.
Guo X; Tie X; Zhang Y; Dai Y; Yao S; Qiao X; Wang L; Su X
Kidney Blood Press Res; 2024; 49(1):345-354. PubMed ID: 38615671
[TBL] [Abstract][Full Text] [Related]
42. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
[TBL] [Abstract][Full Text] [Related]
43. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.
Lv J; Zhang H; Zhou Y; Li G; Zou W; Wang H
Nephrology (Carlton); 2008 Jun; 13(3):242-6. PubMed ID: 18221258
[TBL] [Abstract][Full Text] [Related]
44. Long-term outcome of childhood IgA nephropathy with minimal proteinuria.
Higa A; Shima Y; Hama T; Sato M; Mukaiyama H; Togawa H; Tanaka R; Nozu K; Sako M; Iijima K; Nakanishi K; Yoshikawa N
Pediatr Nephrol; 2015 Dec; 30(12):2121-7. PubMed ID: 26238276
[TBL] [Abstract][Full Text] [Related]
45. IgA nephropathy with minimal change disease.
Herlitz LC; Bomback AS; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1033-9. PubMed ID: 24721885
[TBL] [Abstract][Full Text] [Related]
46. Volume of Crescents Affects Prognosis of IgA Nephropathy in Patients without Obvious Chronic Renal Pathology.
Lin Z; Liu L; Zhang R; Lin X; Lu F; Bao K; Wang L; Lin Q; Mai J; Cao Y; Yang H; Liu X; Zou C
Am J Nephrol; 2021; 52(6):507-518. PubMed ID: 34134110
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
[TBL] [Abstract][Full Text] [Related]
48. Key pathological features characterize minimal change disease-like IgA nephropathy.
Wang TY; Chang FP; Yang AH; Ka SM; Chen A; Hsieh JT; Chen FY; Lee TL; Tseng PY; Tsai MT; Li SY; Yang CY; Chen JY; Lin CC; Tarng DC
PLoS One; 2023; 18(7):e0288384. PubMed ID: 37471324
[TBL] [Abstract][Full Text] [Related]
49. Long-term outcome of IgA nephropathy patients with recurrent macroscopic hematuria.
Le W; Liang S; Chen H; Wang S; Zhang W; Wang X; Wang J; Zeng CH; Liu ZH
Am J Nephrol; 2014; 40(1):43-50. PubMed ID: 24994520
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria.
Tan M; Li W; Zou G; Zhang C; Fang J
Kidney Blood Press Res; 2015; 40(2):200-6. PubMed ID: 25924707
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of massive proteinuria in primary IgA nephropathy with and without nephrotic syndrome: a single center cohort study.
Hu Y; Huang Z; Cao Q; Chen B; Xu S; Qiu W; You X; Zhang J; Chen C
Ren Fail; 2023; 45(2):2267138. PubMed ID: 37850851
[TBL] [Abstract][Full Text] [Related]
52. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
[TBL] [Abstract][Full Text] [Related]
53. Association of obesity with the development of end stage renal disease in IgA nephropathy patients.
Wang S; Qin A; Dong L; Tan J; Zhou X; Qin W
Front Endocrinol (Lausanne); 2023; 14():1094534. PubMed ID: 37020590
[TBL] [Abstract][Full Text] [Related]
54. High serum and urine neutrophil gelatinase-associated lipocalin levels are independent predictors of renal progression in patients with immunoglobulin A nephropathy.
Rhee H; Shin N; Shin MJ; Yang BY; Kim IY; Song SH; Lee DW; Lee SB; Kwak IS; Seong EY
Korean J Intern Med; 2015 May; 30(3):354-61. PubMed ID: 25995666
[TBL] [Abstract][Full Text] [Related]
55. The effects of cytotoxic therapy in progressive IgA nephropathy.
Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
[TBL] [Abstract][Full Text] [Related]
56. CD147 renal expression as a biomarker for progressive IgAN.
Sun S; Zhao A; Li R; Du R; He L; Sun W; Wang H; Huang C
J Nephrol; 2015 Jun; 28(3):307-14. PubMed ID: 25510296
[TBL] [Abstract][Full Text] [Related]
57. Clinical, pathological characteristics and outcomes of immunoglobulin A nephropathy patients with different ages.
Wen Q; Rong R; Zhou Q; Tang X; Yang Q; Chen W; Yu X
Nephrology (Carlton); 2020 Dec; 25(12):906-912. PubMed ID: 31576628
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy.
Park KS; Han SH; Kie JH; Nam KH; Lee MJ; Lim BJ; Kwon YE; Kim YL; An SY; Kim CH; Doh FM; Koo HM; Oh HJ; Kang SW; Choi KH; Jeong HJ; Yoo TH
Hum Pathol; 2014 Feb; 45(2):236-43. PubMed ID: 24439222
[TBL] [Abstract][Full Text] [Related]
59. Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.
Pan M; Zhou Q; Zheng S; You X; Li D; Zhang J; Chen C; Xu F; Li Z; Zhou Z; Zhang J
Immunol Res; 2018 Jun; 66(3):381-391. PubMed ID: 29850970
[TBL] [Abstract][Full Text] [Related]
60. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.
Zittema D; van den Brand JA; Bakker SJ; Wetzels JF; Gansevoort RT
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i146-i153. PubMed ID: 28057871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
